Insider Selling: ASP Isotopes (NASDAQ:ASPI) CEO Sells $306,000.00 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Robert Ainscow sold 22,500 shares of the business’s stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $13.60, for a total transaction of $306,000.00. Following the completion of the sale, the chief executive officer owned 1,647,193 shares of the company’s stock, valued at approximately $22,401,824.80. This represents a 1.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Robert Ainscow also recently made the following trade(s):

• On Monday, September 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The shares were sold at an average price of $8.53, for a total transaction of $71,976.14.

ASP Isotopes Trading Down 9.4%

NASDAQ ASPI opened at $10.01 on Friday. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53. The firm has a market cap of $935.03 million, a PE ratio of -16.41 and a beta of 3.29. The company has a 50 day moving average price of $9.76 and a 200 day moving average price of $8.18. ASP Isotopes Inc. has a 52 week low of $3.65 and a 52 week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. As a group, sell-side analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on ASPI shares. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and an average target price of $11.00.

Institutional Trading of ASP Isotopes

Large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC purchased a new stake in ASP Isotopes during the 2nd quarter worth approximately $9,593,000. Harbour Capital Advisors LLC purchased a new stake in ASP Isotopes during the 2nd quarter worth approximately $232,000. Philadelphia Financial Management of San Francisco LLC grew its position in ASP Isotopes by 11.2% during the 1st quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company’s stock worth $16,453,000 after purchasing an additional 354,517 shares during the last quarter. PFG Investments LLC purchased a new stake in ASP Isotopes during the 1st quarter worth approximately $94,000. Finally, AWM Investment Company Inc. grew its position in ASP Isotopes by 6.2% during the 1st quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company’s stock worth $21,157,000 after purchasing an additional 265,000 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.